Ventyx Biosciences is a clinical-stage biopharmaceutical company developing small-molecule therapies for inflammatory diseases and autoimmune disorders. Its clinical-stage pipeline includes VTX958 (a Phase 1 allosteric TYK2 inhibitor), VTX002 (a Phase 2‑ready S1P1 receptor modulator for ulcerative colitis), and VTX2735 (a Phase 1‑ready peripheral NLRP3 inflammasome inhibitor). The company announced key leadership appointments, including Sheila Gujrathi as Executive Chair and Jörn Drappa as Chief Medical Officer, and added Luisa Salter-Cid and William White to its advisory and board roles. Ventyx says proceeds from its recent financing will strengthen its cash position and accelerate development of its clinical programs. The company is headquartered in Encinitas, California, and is focused on advancing its pipeline toward clinical development milestones. Ventyx Biosciences, based in Encinitas, California, is a clinical-stage biotech advancing a pipeline of potent and selective small-molecule drug candidates for inflammatory and autoimmune diseases. Its internally discovered, wholly-owned portfolio targets gastrointestinal and dermatological indications and combines clinical-stage programs from three companies founded by Raju Mohan and New Science Ventures. Key programs include a tissue-selective S1P1R modulator for IBD (from Oppilan Pharma), a selective allosteric TYK2 inhibitor developed by Ventyx, and an NLRP3 inhibitor program created by Zomagen whose first candidate is slated to enter the clinic in the second half of the year. Ventyx is also leveraging its drug discovery engine to advance preclinical programs against other biologically relevant targets. The company plans to use the $114M financing to fund clinical development of its immunology programs and to advance preclinical programs against novel targets. Led by CEO Raju Mohan, Ventyx emphasizes internal discovery and a broad immunology-focused pipeline.

Total raised

$165M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2021